Quetiapine: efficacy, tolerability and safety in schizophrenia

References

• Tandon R. Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J. Clin. Psychopharmacol.23(3 Suppl. 1), S15–S20 (2003).
   Google Scholar
• Peuskens J. Clinical effectiveness in adults with chronic schizophrenia. Eur. Neuropsychopharmacol.14(Suppl. 4), S453–S459 (2004).
   PubMed Web of Science ®Google Scholar
• Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin. Pharmacother.1(4), 783–801 (2000).
   PubMedGoogle Scholar
• Bridler R, Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med. Wkly133(5–6), 63–76 (2003).
   PubMed Web of Science ®Google Scholar
• Garver DL. Review of quetiapine side effects. J. Clin. Psychiatry61(Suppl. 8), 31–33 (2000).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry63(Suppl. 13), 5–11 (2002).
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst. Rev.(2), CD000967 (2004).
   Google Scholar
• DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet.40(7), 509–522 (2001).
   PubMed Web of Science ®Google Scholar
• Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry24(4), 521–533 (2000).
   PubMed Web of Science ®Google Scholar
• AstraZeneca Seroquel (Quetiapine Fumarate) Tablets. Product monograph. Wilmington (DE), AstraZeneca, (2001).
   Google Scholar
• Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf.23(4), 295–307 (2000).
   PubMed Web of Science ®Google Scholar
• Cheer SM, Wagstaff AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs18(3), 173–199 (2004).
   PubMed Web of Science ®Google Scholar
• Worrel JA, Marken PA, Beckman SE et al. Atypical antipsychotic agents: a critical review. Am. J. Health Syst. Pharm.57(3), 238–255 (2000).
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst. Rev.(3), CD000967 (2000).
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ et al. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol.15(3), 121–131 (2000).
   PubMed Web of Science ®Google Scholar
• Larmo I, Nayer AD, Windhager E et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum. Psychopharmacol.20, 573–581 (2005).
   PubMed Web of Science ®Google Scholar
• Tauscher-Wisniewski S, Kapur S, Tauscher J et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J. Clin. Psychiatry63(11), 992–997 (2002).
   PubMed Web of Science ®Google Scholar
• Ohlsen RI, O’Toole MS, Purvis RG et al. Clinical effectiveness in first-episode patients. Eur. Neuropsychopharmacol.14(Suppl. 4), S445–S451 (2004).
   Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs16(7), 473–484 (2002).
   PubMed Web of Science ®Google Scholar
• Kasper S, Brecher M, Fitton L et al. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int. Clin. Psychopharmacol.19(5), 281–289 (2004).
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin. Ther.24(2), 209–222 (2002).
   PubMed Web of Science ®Google Scholar
• Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum. Psychopharmacol.20(4), 237–241 (2005).
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Goldstein JM, Greenwood M et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin. Ther.25(2), 530–541 (2003).
   PubMed Web of Science ®Google Scholar
• Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr. Med. Res. Opin.20(5), 619–626 (2004).
   PubMed Web of Science ®Google Scholar
• Smith MA, McCoy R, Hamer-Maansson J et al. Rapid dose escalation with quetiapine: a pilot study. J. Clin. Psychopharmacol.25(4), 331–335 (2005).
   PubMed Web of Science ®Google Scholar
• Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum. Exp. Toxicol.20(4), 215–219 (2001).
   PubMed Web of Science ®Google Scholar
• Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics41(1), 63–65 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandes PP, Marcil WA. Death associated with quetiapine overdose. Am. J. Psychiatry159(12), 2114 (2002).
   PubMed Web of Science ®Google Scholar
• Langman LJ, Kaliciak HA, Carlyle S. Fatal overdoses associated with quetiapine. J. Anal. Toxicol.28(6), 520–525 (2004).
   PubMed Web of Science ®Google Scholar
• Kurth J, Maguire G. Pediatric case report of quetiapine overdose and QTc prolongation. Ann. Clin. Psychiatry16(4), 229–231 (2004).
   PubMedGoogle Scholar
• Sokolski KN, Brown BJ, Melden M. Urinary retention following repeated high-dose quetiapine. Ann. Pharmacother.38(5), 899–900 (2004).
   PubMed Web of Science ®Google Scholar
• Good KP, Kiss I, Buiteman C et al. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br. J. Psych. (Suppl. 43), S45–S49 (2002).
   Google Scholar
• Woodward ND, Purdon SE, Meltzer HY et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol.8(3), 457–472 (2005).
   PubMed Web of Science ®Google Scholar
• Kivircik Akdede BB, Alptekin K, Kitis A et al. Effects of quetiapine on cognitive functions in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry29(2), 233–238 (2005).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Prihoda TJ, Sui D et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry64(5), 524–531 (2003).
   PubMed Web of Science ®Google Scholar
• Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J. Clin. Psychiatry63(Suppl. 13), 32–38 (2002).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J. Clin. Psychiatry63(Suppl. 13), 12–20 (2002).
   PubMed Web of Science ®Google Scholar
• Alptekin K, Kivircik BB. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia. Int. Clin. Psychopharmacol.17(5), 263–264 (2002).
   PubMed Web of Science ®Google Scholar
• Gourzis P, Polychronopoulos P, Papapetropoulos S et al. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clin. Neuropharmacol.28(4), 195–196 (2005).
   PubMed Web of Science ®Google Scholar
• Bouckaert F, Herman G, Peuskens J. Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. Int. J. Geriatr. Psychiatry20(3), 287–288 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson MW, Reynolds RR, Kelly DL et al. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin. Neuropharmacol.26(6), 297–298 (2003).
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Kusumi I, Koyama T. A case of tardive dystonia successfully managed with quetiapine. J. Clin. Psychiatry65(4), 583–584 (2004).
   PubMed Web of Science ®Google Scholar
• Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am. J. Psychiatry156(5), 796–797 (1999).
   PubMed Web of Science ®Google Scholar
• Jonnalagada JR, Norton JW. Acute dystonia with quetiapine. Clin. Neuropharmacol.23(4), 229–230 (2000).
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia. Am. J. Psychiatry158(10), 1737 (2001).
   PubMed Web of Science ®Google Scholar
• Sommer BR. Quetiapine-Induced extrapyramidal side effects in patients with Parkinson’s disease: case report. J. Geriatr. Psychiatry Neurol.14(2), 99–100 (2001).
   PubMed Web of Science ®Google Scholar
• Huang SC, Lai TJ, Tsai SJ. A case report of quetiapine-related tic-like symptoms. J. Clin. Psychiatry63(12), 1184–1185 (2002).
   PubMed Web of Science ®Google Scholar
• Kropp S, Hauser U, Ziegenbein M. Quetiapine-associated acute dystonia. Ann. Pharmacother.38(4), 719–720 (2004).
   PubMedGoogle Scholar
• Shim SS. Extrapyramidal symptoms associated with quetiapine. Aust. NZJ Psych.37(6), 773 (2003).
   PubMed Web of Science ®Google Scholar
• Catalano G, Grace JW, Catalano MC et al. Acute akathisia associated with quetiapine use. Psychosomatics46(4), 291–301 (2005).
   PubMed Web of Science ®Google Scholar
• Velayudhan L, Kirchner V. Quetiapine-induced myoclonus. Int. Clin. Psychopharmacol.20(2), 119–120 (2005).
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can. J. Psych.50(11), 703–714 (2005).
   Google Scholar
• Dogu O, Sevim S, Kaleagasi HS. Seizures associated with quetiapine treatment. Ann. Pharmacother.37(9), 1224–1227 (2003).
   PubMed Web of Science ®Google Scholar
• Sussman N. Choosing an atypical antipsychotic. Int. Clin. Psychopharmacol.17(Suppl. 3), S29–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Boyd JA, Pierre JM et al. Delusions associated with quetiapine-related weight redistribution.J. Clin. Psychiatry63(3), 247–248 (2002).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum. Psychopharmacol.19(1), 37–40 (2004).
   PubMed Web of Science ®Google Scholar
• Khawaja IS, Azeem MW, Ebrahim A. Weight loss and anorexia with quetiapine. Psychiatr. Serv.56(4), 490 (2005).
   PubMedGoogle Scholar
• Bobes J, Rejas J, Garcia-Garcia M et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res.62(1–2), 77–88 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J. Clin. Psychiatry66(1), 80–84 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry37(1), 1–11 (2004).
   PubMed Web of Science ®Google Scholar
• Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J. Am. Acad. Child Adolesc. Psychiatry41(5), 495–496 (2002).
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry14(1), 59–64 (2002).
   PubMedGoogle Scholar
• Wirshing DA, Boyd JA, Meng LR et al. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry63(10), 856–865 (2002).
   PubMed Web of Science ®Google Scholar
• Sneed KB, Gonzalez EC. Type 2 diabetes mellitus induced by an atypical antipsychotic medication. J. Am. Board Fam. Pract.16(3), 251–254 (2003).
   PubMedGoogle Scholar
• Sernyak MJ, Leslie DL, Alarcon RD et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry159(4), 561–566 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ohishi S, Katsumi C et al. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry38(4), 183–184 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer JM. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol.21(4), 369–374 (2001).
   PubMed Web of Science ®Google Scholar
• Shaw JA, Lewis JE, Pascal S et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J. Child Adolesc. Psychopharmacol.11(4), 415–424 (2001).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E et al. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr. Res.60(1), 99–100 (2003).
   PubMedGoogle Scholar
• Atmaca M, Kuloglu M, Tezcan E et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J. Clin. Psychiatry64(5), 598–604 (2003).
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology31(3), 340–346 (2005).
   PubMed Web of Science ®Google Scholar
• Montejo Gonzalez AL, Rico-Villademoros F, Tafalla M et al. A 6-month prospective observational study on the effects of quetiapine on sexual functioning. J. Clin. Psychopharmacol.25(6), 533–538 (2005).
   PubMed Web of Science ®Google Scholar
• Knegtering R, Castelein S, Bous H et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J. Clin. Psychopharmacol.24(1), 56–61 (2004).
   PubMed Web of Science ®Google Scholar
• Bobes J, Garc A-Portilla MP, Rejas J et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J. Sex Marital Ther.29(2), 125–147 (2003).
   PubMed Web of Science ®Google Scholar
• du Toit RM, Millson RC, Heaton JP et al. Priapism. Can. J. Psych.49(12), 868–869 (2004).
   Google Scholar
• Davol P, Rukstalis D. Priapism associated with routine use of quetiapine: case report and review of the literature. Urology66(4), 880 (2005).
   Google Scholar
• Atmaca M, Kuloglu M, Tezcan E. A new atypical antipsychotic: quetiapine-induced sexual dysfunctions. Int. J. Impot. Res.17(2), 201–203 (2005).
   PubMed Web of Science ®Google Scholar
• Alexiadis M, Whitehorn D, Woodley H et al. Prolactin elevation with quetiapine. Am. J. Psychiatry159(9), 1608–1609 (2002).
   PubMed Web of Science ®Google Scholar
• Orlandi V, Speca A, Salviati M et al. Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of opioid system. J. Clin. Psychopharmacol.23(6), 677–679 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J. Child Adolesc. Psychopharmacol.15(6), 893–900 (2005).
   PubMed Web of Science ®Google Scholar
• de Borja GGA, Castel S, Benedito-Silva AA et al. Neuroendocrine effects of quetiapine in healthy volunteers. Int. J. Neuropsychopharmacol.8(1), 49–57 (2005).
   PubMed Web of Science ®Google Scholar
• Tenyi T, Trixler M, Keresztes Z. Quetiapine and pregnancy. Am. J. Psychiatry159(4), 674 (2002).
   PubMedGoogle Scholar
• Taylor TM, O’Toole MS, Ohlsen RI et al. Safety of quetiapine during pregnancy. Am. J. Psychiatry160(3), 588–589 (2003).
   PubMed Web of Science ®Google Scholar
• Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann. Pharmacother.38(7–8), 1265–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Lee A, Giesbrecht E, Dunn E et al. Excretion of quetiapine in breast milk. Am. J. Psychiatry161(9), 1715–1716 (2004).
   PubMed Web of Science ®Google Scholar
• McKenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J. Clin. Psychiatry66(4), 444–449 (2005).
   PubMed Web of Science ®Google Scholar
• Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr. Pharm. Des.10(20), 2463–2475 (2004).
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta. Psychiatr. Scand.112(4), 318–322 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta S, Nienhaus K, Shah SA. Quetiapine and QTc issues: a case report. J. Clin. Psychiatry64(5), 612–613 (2003).
   PubMedGoogle Scholar
• Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim. Care Companion J. Clin. Psychiatry5(5), 205–215 (2003).
   Google Scholar
• Roesch-Ely D, Van Einsiedel R, Kathofer S et al. Myocarditis with quetiapine. Am. J. Psychiatry159(9), 1607–1608 (2002).
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Becker HE, Jessurun P et al. Agranulocytosis and granulocytopenia associated with quetiapine. Acta. Psychiatr. Scand.104(4), 311–313 (2001).
   PubMed Web of Science ®Google Scholar
• Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine. Psychosomatics42(4), 368 (2001).
   PubMed Web of Science ®Google Scholar
• Oluboka O, Haslam D, Lam T et al. Quetiapine-induced leucopenia: possible dosage-related phenomenon. Can. J. Psych.48(1), 65–66 (2003).
   Google Scholar
• Nair P, Lippmann S. Is leukopenia associated with divalproex and/or quetiapine? Psychosomatics46(2), 188–189 (2005).
   PubMed Web of Science ®Google Scholar
• Clark N, Weissberg E, Noel J. Quetiapine and leukopenia. Am. J. Psychiatry158(5), 817–818 (2001).
   PubMed Web of Science ®Google Scholar
• Iraqi A. A case report of pancytopenia with quetiapine use. Am. J. Geriatr. Psychiatry11(6), 694 (2003).
   PubMed Web of Science ®Google Scholar
• Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann. Pharmacother.39(7–8), 1346–1348 (2005).
   PubMed Web of Science ®Google Scholar
• Whitehorn D, Gallant J, Woodley H et al. Quetiapine treatment in early psychosis: no evidence of cataracts. Schizophr. Res.71(2–3), 511–512 (2004).
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. Am. J. Ophthalmol.138(5), 870–871 (2004).
   PubMed Web of Science ®Google Scholar
• Shahzad S, Suleman MI, Shahab H et al. Cataract occurrence with antipsychotic drugs. Psychosomatics43(5), 354–359 (2002).
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Buyukbayram A et al. Quetiapine-associated and dose-related hypomania in a woman with schizophrenia. Eur. Psychiatry17(5), 292–293 (2002).
   PubMed Web of Science ®Google Scholar
• Lykouras L, Oulis P, Hatzimanolis J. Manic symptoms associated with quetiapine treatment. Eur. Neuropsychopharmacol.13(2), 135–136 (2003).
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Manfredi G, Kotzalidis GD et al. Quetiapine-induced mania. Aust. NZJ Psych.37(5), 626 (2003).
   PubMed Web of Science ®Google Scholar
• Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorder. Can. J. Psych.46(2), 182–183 (2001).
   Google Scholar
• Mergui J, Jaworowski S, Lerner V. Quetiapine-associated depression in a patient with schizophrenia. Clin. Neuropharmacol.28(3), 133–135 (2005).
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Westerman EM, Boswijk DJ et al. Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. Ther. Drug Monit.28(2), 185–189 (2006).
   PubMed Web of Science ®Google Scholar
• Balit CR, Isbister GK, Hackett LP et al. Quetiapine poisoning: a case series. Ann. Emerg. Med.42(6), 751–758 (2003).
   PubMed Web of Science ®Google Scholar
• Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs17(5), 307–324 (2003).
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Krenz S, Zullino DF. Quetiapine overdose associated with alcohol intoxication. German J. Psychiatry7, 60–61 (2004).
   Google Scholar
• Lacro JP, Dunn LB, Dolder CR et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry63(10), 892–909 (2002).
   PubMed Web of Science ®Google Scholar
• Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res.28(2–3), 199–206 (1997).
   PubMed Web of Science ®Google Scholar
• Llorca PM, Vaiva G, Lancon C. Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal. Can. J. Psych.46(1), 87–88 (2001).
   Google Scholar
• Ekblom B, Eriksson K, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl.)83(3), 293–294 (1984).
   PubMed Web of Science ®Google Scholar
• Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J. Clin. Psychiatry58(6), 252–255 (1997).
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Beauclair L et al. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol.22(4), 347–352 (2002).
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J et al. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J. Clin. Psychiatry66(12), 1512–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Thurstone CC, Alahi P. A possible case of quetiapine withdrawal syndrome. J. Clin. Psychiatry61(8), 602–603 (2000).
   PubMedGoogle Scholar
• Pierre JM, Shnayder I, Wirshing DA et al. Intranasal quetiapine abuse. Am. J. Psychiatry161(9), 1718 (2004).
   PubMed Web of Science ®Google Scholar
• Koro CE, Meyer JM. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent. Psychopharmacol.6(3), 148–157 (2005).
   PubMedGoogle Scholar
• Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J. Clin. Psychiatry63(Suppl. 13), 21–26 (2002).
   PubMedGoogle Scholar
• Kopala LC, Good KP, Milliken H et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr. Res.81(1), 29–39 (2006).
   PubMed Web of Science ®Google Scholar